Skip to content

Efficacy and safety of fractional picosecond-domain laser (PSL) for atrophic traumatic and surgical scars : A randomized split-scar study

Efficacy and safety of fractional picosecond-domain laser (PSL) for atrophic traumatic and surgical scars : A randomized split-scar study

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210302003
Enrollment
25
Registered
2021-03-02
Start date
2021-01-19
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fractional picosecond-domain laser (PSL) for atrophic traumatic and surgical scars Atrophic traumatic Atrophic surgical scars Fractional picosecond-domain laser

Interventions

Each participant was given two equal parts of the scar then one side of the scar was randomized for treatment with fractional picosecond-domain laser and the other side was controlled. The side of tre
Treatment group with fractional picosecond-domain laser ,control group

Sponsors

Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male or female participants, aged 18-65. 2. Participants had s atrophic dramatic scar or atrophic surgical scar more than 2 cm. for more than 1 year in any position of the body. 3. Participants who are willing to join the project after receiving a detailed description of the project and signing a consent form for the study. 4. Participants can follow the testing method to follow up on treatment results throughout the study period and can report side effects that arise from the study immediately.

Exclusion criteria

Exclusion criteria: 1. Participant with a previous history of keloid scars. 2. Participants had a history of using systemic retinoids (acitretin, isotretinoin) within 6 months prior to the start of the study. 3.Participants have a history of treatment for atrophic scar such as topical vitamin A, topical drugs that exfoliate or exfoliate skin, microdermabrasion, and chemical peeling. Before, within 6 months prior to the start of research 4. Participants who are pregnant, breastfeeding, or planning to become pregnant. 5. Participants had a history of connective tissue disease. 6. Participants who took immunosuppressants (Immunosuppressive agents) 7. Participants with any type of diabetes mellitus. 8. Participants with diseases that make ulcers difficult to heal, such as sclerosis, peripheral arterial disease, etc. 9. Participant with infectious conditions in the treated area such as herpes, acne, cellulitis, etc. 10. Participants with a history of local anesthesia.

Design outcomes

Primary

MeasureTime frame
scar volume at 6 months after first of the intervention skin imaging analysis (Antera3Dsystem)

Secondary

MeasureTime frame
Patient satisfactions at 6 months after first of the intervention Satisfaction assessment form,pain score every time after treatment pain score assessment form,adverse event after treatment every time after treatment adverse event assessment form,The efficacy of the treatment at 6 months after first of the intervention dermatologist,The density of collagen and elastin fibers. at 6 months after first of the intervention skin biopsy

Countries

Thailand

Contacts

Public ContactWareeporn Disphanurat

Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University, Thailand

dwareeporn@gmail.com029269435

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026